A validated stability indicating HPLC method for the determination of Valsartan in tablet dosage forms.

Journal of Applied Pharmaceutical Science

Volumn 1, Issue 4, 2011, Pages 97-99

  Parambi, Della Grace Thomas ^a   Mathew, Molly ^b   Ganesan, V ^c  

^a AMRITA INSTITUTE OF MEDICAL SCIENCES   (India)

^b Malik Deenar College of Pharmacy   (India)

^c Erode College of Pharmacy   (India)

Author keywords

Ammonium dihydrogen phosphate buffer; HPLC; Methanol; Validation; Valsartan

Indexed keywords

EID: 84875909269     PISSN: None     EISSN: 22313354     Source Type: Journal    
DOI: None     Document Type: Article

References (8)

1. Flesch G., Muller P and Lloyd P. Absolute bioavailability and pharmacokinetics of valsartan, an angiotensin II receptor antagonist, in man.Eur J Clin Pharmacol. 1997; 52: 115- 120.
2. Gonzalez L., Lopez J.A., Alonso R.M. and Jimenez R.M. Fast screening method for the determination of angiotensin II receptor antagonists in human plasma by high-performance liquid chromatography with fluorimetric detection. J Chromatogra A. 2002; 949(1-2):49-60
3. Habib IH.I., Weshahy I.and Toubar, S.A. Stripping voltametric determination of valsartan in bulk and pharmaceutical products.Pramazie., 2008, 63 ,5 ,337-341
4. Huber, L.,Validation of analytical methods:Review and strategyLC/GC international.Lab compliance 1998, 96.
5. Kocyigit-Kaymakcoglu., Unsalan.and Roll,S. Determination and validation of Ketoprofen, Pantoprazole and Valsartan together in human plasma by high performance liquid chromatography. Pharmazie. 2006; 61(7):586-9. Pharmazie., 2006, 61, 7, 586.
6. Macek J., Klíma J. and Ptacek P., Rapid determination of Valsartan in human plasma by protein precipitation and highperformance liquid chromatography. J Chromatogr B Analyt Technol Biomed Life Sci. 2006; 832(1):169-72.
7. Nevin Erk. Spectrophotometric analysis of valsartan and hydrochlorothiazide. Analytical Letters.2002; 35(2):283-302.
8. Tatar S and Saglík S. Comparison of UV- and second derivative-spectrophotometric and LC methods for the determination of Valsartan in pharmaceutical formulation. J Pharmaceut and Biomed Anal.2002; 30(2):371-375.